Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer An Italian Multicenter Retrospective Study

Gadducci, Angiolo; Cosio, Stefania; Zola, Paolo; Sostegni, Benedetta; Fuso, Luca; Sartori, Enrico

doi:10.1097/igc.0b013e318286665b

Cited by 22 publications

(23 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported in different early-stage EOC-dedicated studies (11)(12)(13), both univariate and multivariate analyses did not reveal any difference in survival rates among different histotypes. The grade of tumor was the most significant prognostic feature: increasing grade at the time of diagnosis was associated to decrease in patient survival (Supplementary Section S2).…”

Section: Patient Characteristicssupporting

confidence: 62%

miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities

Calura

Fruscio

Paracchini

et al. 2013

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic diseases, with survival rate virtually unchanged for the past 30 years. EOC comprises different histotypes with molecular and clinical heterogeneity, but up till now the present gold standard platinum-based treatment has been conducted without any patient stratification. The aim of the present study is to generate microRNA (miRNA) profiles characteristic of each stage I EOC histotype, to identify subtype-specific biomarkers to improve our understanding underlying the tumor mechanisms.Experimental Design: A collection of 257 snap-frozen stage I EOC tumor biopsies was gathered together from three tumor tissue collections and stratified into independent training (n ¼ 183) and validation sets (n ¼ 74). Microarray and quantitative real-time PCR (qRT-PCR) were used to generate and validate the histotype-specific markers. A novel dedicated resampling inferential strategy was developed and applied to identify the highest reproducible results. mRNA and miRNA profiles were integrated to identify novel regulatory circuits.Results: Robust miRNA markers for clear cell and mucinous histotypes were found. Specifically, the clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a Ã , whereas mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore, a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified. Conclusions: Our findings showed that stage I EOC histotypes have their own characteristic miRNA expression and specific regulatory circuits. Clin Cancer Res; 19(15); 4114-23. Ó2013 AACR.

show abstract

Section: Patient Characteristicssupporting

confidence: 62%

miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities

Calura

Fruscio

Paracchini

et al. 2013

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recurrent disease was detected in 19% of the patients, which is consistent with the recurrence rates reported in other studies (10-30%) [6,7,13,25,26,27]. In the present study, adjuvant chemotherapy was not significantly associated with RFS and OS regardless of the staging procedure.…”

Section: Discussionsupporting

confidence: 82%

Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer

Frielink¹,

Pijlman²,

Ezendam³

et al. 2016

Chemotherapy

View full text Add to dashboard Cite

Background: Adjuvant platinum-based chemotherapy improves survival in women with early-stage epithelial ovarian cancer (EOC). Yet, there is a wide variety in clinical practice. Methods: All patients diagnosed with FIGO I and IIa EOC (2006-2010) in the south of the Netherlands were analyzed. The percentage of patients that received adjuvant chemotherapy was determined as well as the comprehensiveness of staging and outcome. Results: Forty percent (54/135) of the patients with early-stage EOC received adjuvant chemotherapy. Treatment with adjuvant chemotherapy was associated with FIGO stage, clear-cell histology and nonoptimal staging. Optimal staging was achieved in 50%, and nonoptimal staging was associated with advanced age, comorbidity and treatment in a non-referral hospital. Overall, there was no difference in outcome between patients with and without adjuvant chemotherapy. Yet, in grade 3 tumors, adjuvant chemotherapy seems beneficial. Conclusions: Selective treatment of patients with early-stage EOC might reduce adjuvant chemotherapy without compromising outcome.

show abstract

“…FIGO classification was used for histological grading and disease staging. 13 The date of the first positive cytology or the date of the primary surgery in patients without cytology before primary surgery was defined as the date of diagnosis. The front-line chemotherapy regimen was platinum-paclitaxel for patients who were eligible for chemotherapy.…”

Section: Methodsmentioning

confidence: 99%

<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>

Khalafi-Nezhad

Ebrahimi

Ahmadpour

et al. 2020

CMAR

View full text Add to dashboard Cite

This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). Methods: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. Results: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2-5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. Conclusion: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients.

show abstract

Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer An Italian Multicenter Retrospective Study

Abstract: Patient age and surgery at recurrence were independent prognostic variables for patients with recurrent early-stage ovarian cancer. When feasible, salvage surgery appears to give a survival advantage in this clinical setting.

Cited by 22 publications

References 32 publications

miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities

miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities

Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer

<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>

Contact Info

Product

Resources

About